SCHEMBL4021774

SCHEMBL4021774

Cc1c(I)cccc1C1C(C(=O)c2ccccc2)CN(CC(=O)N(C)C)CC1C(=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.34
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
GRIN2B Q13224 3/20 0.32
KCNH2 Q12809 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
KIF11 P52732 1/20 0.32
CYP2D6 P10635 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
RECQL P46063 1/20 0.32
ALDH1A1 P00352 1/20 0.31
DRD4 P21917 1/20 0.31
HRH1 P35367 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021771 1.00 RORC (0.34) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4028137 0.91 RORC (0.37) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4028139 0.91 RORC (0.37) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4024526 0.89 KIF11 (0.37) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4020347 0.89 KIF11 (0.37) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4020344 0.89 KIF11 (0.37) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4019982 0.87 KMT2A (0.39) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4019987 0.87 KMT2A (0.39) RORCKDM4ENPC1LMNARAB9A
SCHEMBL4021412 0.87 RORC (0.36) RORCKCNH2MEN1KMT2ACYP2D6
SCHEMBL4021408 0.87 RORC (0.36) RORCKCNH2MEN1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 RORC 183/4885KDM4E 4110/4885NPC1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.